Author:
Singh Aman P.,Guo Leiming,Verma Ashwni,Wong Gloria Gao-Li,Thurber Greg M.,Shah Dhaval K.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, et al. Evolution of antibody- drug conjugate tumor disposition model to predict preclinical tumor pharmacokinetics of Trastuzumab-emtansine (T-DM1). AAPS J. 2016;18(4):861–75.
2. Teicher BA. Antibody drug conjugates. Curr Opin Oncol. 2014;26(5):476–83.
3. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17(20):6389–97.
4. Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. J Clin Immunol. 2016;36(Suppl 1):100–7.
5. Mistri F. Where do ADCs sit in the clinical landscape? Comparison of ADCs with current standard of care: World ADC 2017, Berlin; 2017.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献